On Thursday, AbbVie Inc. announced positive findings from the LEVEL UP Phase 3b/4 study. This study compared the efficiency and safety of AbbVie's drug Upadacitinib, or Rinvoq, to Regeneron Pharmaceuticals and Sanofi's drug, Dupilumab, also known as Dupixent. The trial specifically focused on the use of these drugs to treat moderate-to-severe atopic dermatitis in adults and teenagers.
Rinvoq outperformed Dupixent, as it was more effective at hitting predefined levels of improved skin health. The trial used specific clinical scores, such as 90% reduction or greater in the Eczema Area and Severity Index and a Dermatology Life Quality Index of 0 or 1 at the 16-week point.
The results also demonstrated Rinvoq's superior performance over Dupixent on all secondary outcomes, which included more rapid progress towards complete skin clearance and reduced itching.
AbbVie plans to share the full results of this LEVEL UP study at an forthcoming medical conference.
